Align Technology (ALGN)
(Delayed Data from NSDQ)
$249.46 USD
+7.01 (2.89%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $249.42 -0.04 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$249.46 USD
+7.01 (2.89%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $249.42 -0.04 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
Zacks News
Factors Setting Stage for CVS Health's (CVS) Q1 Earnings
by Zacks Equity Research
CVS Health (CVS) expects robust 2018 PBM selling season and strong Pharmacy Services segment to drive earnings in Q1.
Can ResMed (RMD) Repeat Stable Device Growth in Q3 Earnings?
by Zacks Equity Research
ResMed's (RMD) sleep apnea patient volume consistently witnesses a steady expansion. We expect this upside to continue in the fiscal third quarter as well.
Quest Diagnostics (DGX) Q1 Earnings Meet, Guidance Intact
by Zacks Equity Research
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q1 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Can Steady Overall Growth Drive Align's (ALGN) Q1 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is likely to gain from strength in the Invisalign space as well as Scanner and Service business in Q1.
Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained
by Zacks Equity Research
Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.
Henry Schein Ties Up With Internet Brands to Boost Dental Arm
by Zacks Equity Research
Henry Schein (HSIC) banks on part of its strategic plan, digital dentistry. In this regard, its latest joint venture with Internet Brands buoys optimism.
Zacks.com featured highlights include: Amazon.com, Align, Axon Enterprise, Antero and Jones Lang
by Zacks Equity Research
Zacks.com featured highlights include: Amazon.com, Align, Axon Enterprise, Antero and Jones Lang
Company News For April 6, 2018
by Zacks Equity Research
Companies In The News are: MON,BAYN,GMS,CYOU,ALGN
Get Earnings Surprise From 5 Top Stocks & Beat Market Blues
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next releases.
Align Unveils Vivera Retainers for Deep Bite Correction
by Zacks Equity Research
Align (ALGN) hopes to taste greater clinical success in the orthodontic space with Vivera Retainers' integration into Precision Bite Ramps, which are part of the company's Invisalign G5.
Align Technology Broadens Invisalign Suite, Extends Reach
by Zacks Equity Research
Align Technology (ALGN) leaves no stone unturned to boost the Invisalign product portfolio and strengthen its hold in the high-potential invisible orthodontics market.
Myriad Genetics' BRACAnalysis Test Platform Gets PMA in Japan
by Zacks Equity Research
Myriad Genetics (MYGN) leaves no stone unturned to boost uptake of BRACAnalysis test and strengthen the Molecular Diagnostics portfolio.
Ensign Group Boosts Arizona Base With Real Estate Buyout
by Zacks Equity Research
Ensign Group's (ENSG) inclination toward inorganic growth leads to numerous acquisitions, significantly favoring the company's top line.
Boston Scientific to Acquire Securus Medical, Boost EP Unit
by Zacks Equity Research
Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.
Dental Implant & Prosthetic Boom Puts Spotlight on 3 Stocks
by Gargi Seth
The dental market has outperformed the broader market in last ten years on the back of demand from both teenagers and adults.
Will Walgreens' (WBA) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Walgreens Boots' (WBA) increase in sales at the Retail Pharmacy International segment, on account of the company's strategic tie-ups, along with strength in other businesses buoy optimism.
Align Technology Banks on Global Growth, Competition Rife
by Zacks Equity Research
We are encouraged by Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in Asia Pacific.
Align Technology (ALGN) Q4 Earnings Top on Invisalign Sales
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from the Clear Aligner as well as Scanner and Service segments in Q4.
Post-Market Q4 Earnings Parade: SFLY, ALGN & More
by Mark Vickery
Following today's closing bell, we see fresh quarterly earnings results from a host of new companies.
Can Invisalign Drive Align Technology's (ALGN) Q4 Earnings?
by Zacks Equity Research
Align Technology (ALGN) poised to gain from strength in the Invisalign space as well as Scanner and Service business in Q4.
Align Rides on Balanced Segmental Growth Amid Stiff Contest
by Zacks Equity Research
Align (ALGN) gains from balanced sales growth across all its channels of late, primarily on high InvisAlign Technology case volumes.
Universal Health Grows Inorganically, Rising Costs a Drag
by Zacks Equity Research
Universal Health's (UHS) top line grows on solid Acute Care and Behavioral Health platforms. Nevertheless, surging level of debt bothers.
Zimmer Biomet Strong on Positive Data From PROGRESS II Study
by Zacks Equity Research
Zimmer Biomet (ZBH) consistently endeavors to improve its knee business.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) rides high on its solid guidance. The company's recent FDA approval is also encouraging.
Haemonetics Banks on Hospital Business, Competition Rife
by Zacks Equity Research
For fiscal 2018, Haemonetics (HAE) expects the Hospital business to grow 7-10%.